What is Bantam Pharmaceutical?
Bantam Pharma is dedicated to pioneering novel, first-in-class small molecule oral therapeutics for challenging hematological and solid tumors. Their primary candidate, BTM-3566, is designed to restore apoptosis in cancer cells, demonstrating promising preclinical outcomes, particularly against Diffuse Large B-cell Lymphoma. The company's strategic focus on mitochondrial dynamics positions it for aggressive product development within the oncology sector, operating with a capital-efficient model.
How much funding has Bantam Pharmaceutical raised?
Bantam Pharmaceutical has raised a total of $25M across 1 funding round:
Angel/Seed
$25M
Angel/Seed (2021): $25M, investors not publicly disclosed
What's next for Bantam Pharmaceutical?
The recent major enterprise-level funding indicates a pivotal stage for Bantam Pharmaceutical, likely enabling the advancement of its lead candidate, BTM-3566, into clinical trials. This strategic investment will be crucial for scaling operations, expanding research and development efforts, and potentially forging key partnerships to accelerate the path to market for its innovative cancer treatments. The company's trajectory suggests a strong focus on achieving significant milestones in oncology therapeutics.
See full Bantam Pharmaceutical company page
